
|Videos|November 22, 2013
Targeting KRAS in Colorectal Cancer
Author(s)Charles S. Fuchs, MD, MPH
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.
Advertisement
Clinical Pearls
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targetingKRASin colorectal cancer.
- KRASis mutated in 40% of patients and defines who should get cetuximab or panitumumab
- Patients should be genotyped for all mutations inKRASandNRAS
- Defining drug targets against mutantKRAShas been impossible thus far
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































